China News Service, Guangzhou, August 17 (Reporter Cai Minjie) In recent years, with the advancement of cancer treatment methods, the survival status of lung cancer patients in my country has improved.

"With the introduction of immunotherapy into China, compared with the past era of chemotherapy alone and targeted therapy, both research data and real clinical cases have confirmed that the survival rate of cancer patients has indeed improved to a higher level." China Thoracic Cancer Research Collaboration Professor Wu Yilong, chairman of the group (CTONG) and lifelong director of the Guangdong Provincial People's Hospital, said recently that on this basis, the medical community has changed from making lung cancer a chronic disease proposed in the past, to now advocating making lung cancer curable, lung cancer A qualitative leap has been achieved in treatment and management.

　　Lung cancer is the cancer with the highest morbidity and mortality in my country.

According to the latest global cancer burden data in 2020 released by the World Health Organization's International Agency for Research on Cancer, there will be 820,000 new lung cancer cases and 710,000 deaths in China in 2020, much higher than other cancers.

In recent years, with the advancement of cancer treatment methods, the survival status of lung cancer patients in my country has been significantly improved. The five-year survival rate of patients has increased from 5% in the era of radiotherapy and chemotherapy to about 15% today.

　　Lung cancer can be divided into non-small cell lung cancer and small cell lung cancer according to histopathological characteristics, among which non-small cell lung cancer accounts for about 80% to 85% of all lung cancers, and small cell lung cancer accounts for about 15%.

Since the advent of targeted therapy, many patients with advanced non-small cell lung cancer who are inoperable and intolerant of radiotherapy and chemotherapy have also achieved long-term survival and higher quality of life, but for patients with driver gene-negative non-small cell lung cancer and small cell lung cancer patients. , targeted therapy does not meet their therapeutic needs.

In recent years, the listing and wide application of immunosuppressants have brought new treatment options to these patients.

　　"Currently, immunotherapy for lung cancer refers to 'immune checkpoint inhibitors', which refers to a series of immune-related treatments that use the body's own immune system to destroy tumor cells. The effect of immunotherapy is mild, such as PD-1/PD-L1 monoclonal antibody." Wu Yilong said, "Compared with the traditional treatment plan, the efficacy of immunotherapy is long-lasting, the time span is also larger, it has a good tailing effect, and it is not bad. The overall incidence of reactions is lower than that of chemotherapy, and most immune-related adverse reactions are reversible.”

　　Today, immunotherapy has become the fifth mainstream treatment for tumors after surgery, radiotherapy, chemotherapy and targeted therapy, benefiting advanced squamous cell carcinoma and non-squamous non-small cell lung cancer without driver gene mutation, stage III unresectable non-small cell lung cancer Small cell lung cancer, extensive stage small cell lung cancer and more different types of patients.

　　At present, there are 9 PD-(L)1 mAbs approved for lung cancer indications in China, including 4 imported drugs and 5 domestic drugs.

In this regard, Wu Yilong said that different PD-(L)1 mAbs have different indications, and these drugs are not mutually replaceable. Immunotherapy for lung cancer should strictly follow the indications and use them rationally.

　　"At present, my country has made great efforts to standardize treatment, which is mainly reflected in the writing of guidelines. The characteristics of guidelines are that there must be very persistent evidence, and these evidences come from large-scale randomized controlled studies around the world. On this basis, the Chinese National Health Service The National Health Commission also entrusted the National Health Commission's Rational Drug Use Expert Committee to draft guidelines, and the effects of the guidelines exceeded the guidelines. However, the most powerful is medical insurance, and the reimbursement stipulated by medical insurance is used according to the approved indications, and this series of The combination of these technologies has promoted the development of standardized diagnosis and treatment in my country," Wu Yilong said.

(Finish)